References:-

1. **Ana Lucia, Peixoto de Freitas and Afonso Luis Barth**. Antibiotic resistance and molecular typing of *Pseudomonas aeruginosa*: Focus on Imipenem. The Brazilian Journal of Infectious Diseases.2002;6(1):1-7.
2. **Anzai Y, Kim H, Park , JY, Wakabayashi H, Park, JY, Wakabayashi H.** Phylogenetic affiliation of the *Pseudomonads* based on 16SrRNA sequence. *Int J Syst Evol Microbiology*.2000;50:1563-89.
3. **Bonomo RA, Szabo D.** Mechanisms of multidrug resistance in *Acinetobacter* species and *Pseudomonas aeruginosa*. Clin Infect Dis 2006;43 Suppl 2: 49-56.
4. **Bush K, Jacoby GA, Medeiros AA.** A functional classification scheme for b-lactamases and its correlation with molecular structure. Antimicrobial Agents Chemother.1995; 39:1211-33.
5. **Y.W. Chu, M. Afjal-Shah, Elizabeth T.S. Houang, M.F.I. Palepou, Donald J. Lyon, Neil Woodford, and D.M. Livermore.** IMP-4 a novel metallo β-lactamase from nosocomial Acinetobacter spp. Collected in Hong Kong between 1994 and 1998. Antimicrob. Agents Chemother. 2001, 45: 710-714.
6. **National Nosocomial Infections surveillance (NNIS)** System Report, data summary from January 1992 through june 2004, issued October 2004. Am J Infect Control 2004;32:470-85.
7. **Bell JM, Turnidge JD, Gales AC, Pfaller MA, Jones RN.** Prevalence of extended spectrum beta-lactamase (ESBL) producing clinical isolates in the Asia-Pacific region and south Africa: regional results from SENTRY Antimicrobial surveillance program(1998-99). Diagn Microbiol Infect Dis 2002;42:193-8.
8. **Falagas ME, Bliziotis IA.** Pandrug-resistant gram-negative bacteria: the dawn of the post-antibiotic era? Int J Antimicrob Agents 2007;29:630-6.
9. **Nordmann P, Poirel L.** Emerging carbapenemases in gram negative aerobes. Clin. Microbiol. Infect. 2002, 8: 321-333.
10. **Walsh TR, Toleman MA, Poirel L, Nordman P.** Metallo β-lactamases: the quiet before storm? Clin. Microbiol. Rev. 2005, 18: 306-325.
11. **Deeba Bashir, Manzoor Ahmad Thokar,Bashir Ahmad Fomda, Gulnaz Bashir, Danish Zahoor, Shabir Ahmad and Abubaker S. Toboli.** Detection of metallo-beta-

lactamase (MBL) producing *Pseudomonas aeruginosa* at a tertiary care hospital in Kashmir. African Journal of Microbiology Research 2011; 5(2): 164-172.

12. **Valenza G, Joseph B, Elias J, Claus H, Oetterlein A, EngelHardt K, Turnwald D, Frosch M, Abele-Horn M Schoen C.** First survey of Metallo-β-lactamases in clinical isolates of pseudomonas aeruginosa in a German university hospital. *Antimicrob Agents Chemother* 2010; 54: 3493-3497.
13. **Lauretti L, M L Riccio, A. Mazzariol G. Cornaglia G. Amicosante, R.Fontana, G. M.Rossolini**. Cloning and characterization of *bla*VIM, a new integron-borne metallo-β-lactamase gene from a *Pseudomonas aeruginosa* clinical isolate. Antimicrob. Agents hemother. 1999; 43:1584–90.
14. **Nordmann P, Cuzon G, Naas T**.The real threat of *Klebsiella pneumoniae* carbapenemase-producing bacteria.*Lancet Infect Dis.* 2009;9 :228-236.(**2012,Richard O**)
15. **Pitout JD, Chow BL, Gregson DB, Laupland KB, Elsayed S, Chruch DL.** Molecular epidemiology of metallo-β-lactamase producing *Pseudomonas aeruginosa* in the Calgary Health Region: Emergence of VIM-2 Producing Isolates. J. Clin. Microbiol. 2007, 45: 294-298.
16. **Marra AR, Pereira CA, Gales AC, Menezes LC, Cal RG, desouza JM.** Blood stream infections with metallo-β-Lactamase- producing *Pseudomonas aeruginosa*: Epidemiology, Microbiology and clinical outcomes. Antimicrob. Agents Chemother. 2006, 50: 388-390.
17. **Van der Bij AK, Van Mansfeld R, Peirano G, Goessens WH, *et al*.** (2011). First outbreak of VIM-2 metallo-β-lactamase-producing Pseudomonas aeruginosa in The Netherlands: microbiology, epidemiology and clinical outcomes. *Int J Antimicrob Agents* **37**(6), 513-518
18. **Livermore, D.M., and N. woodford.** Carbapenemases: aproblem in waiting? Curr. Opin. Microbiol 2000; 3:489-495.
19. **Clare Franklin, Lisa Liolios and Anton Y. Peleg.** Phenotypic detection of carbapenem- susceptible metallo-β-lactamase producing gram negative bacilli in clinical laboratory. J. Clin. Microbiol. 2006; 44: 3139-3144.
20. **Laupland KB, MD Parkins, DL Church, DB Gregson, TJ Louie, JM Conly, S. Elsayed and JD Pitout.** Population based epidemiological study of infections caused

by carbapenem resistant Pseudomonas aeruginosa in the Calgary Health region: Importance of metallo-beta-lactamase (MBL) producing strains. J. Infect. Dis. 2005; 192: 1606-1612.

21. **Peleg AY, C. Franklin, JM Bell and DW Spelman**. Dissemination of the metallo-beta lactamase gene *bla*IMP-4 among gram negative pathogens in a clinical setting in Australia. Clin. Infect Dis. 2005;41:1549-1556.
22. **Andrews JM..** BSAC standardized disc susceptibility testing metho (version 4). J. Antimicrob. Chemother 2005; 56:60–76.
23. **Tibbetts R, Frye JG, Marschall J, et al.** Detection of KPC-2 in a clinical isolate of Proteus mirabilis and first reported description of carbapenemase resistance caused by a KPC beta-lactamase in P mirabilis. J Clin Microbiol. 2008;46:3080-3083.
24. **Bratu S, Landman D, Haag R, et al.** Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City:a new threat to our antibiotic armamentarium. Arch Intern Med. 2005;165:1430-1435.
25. **Queenan AM, Bush K.** Carbapenemases: the versatile betalactamases. Clin Microbiol Rev. 2007;20:440-458, table of contents.
26. **Eisenstein BI, Zaleznik DF. Enterobacteriaceae. In: Mandell GL, Bennett JE, Dolin R,** editors. Principles and practice of infectious diseases, 5th ed. Philadelphia, Pa: Churchill Livingstone; 2000 p. 2294-310.
27. **Saderi H, Lotfalipour H, Owlia P, Salimi H.** Detection of Metallo-β-lactamase producing *Pseudomonas aeruginosa* isolated from burn patients in Teheran, Iran. Lab Med. 2010;41:609–12
28. **Koneman's Color Atlas & Textbook of Diagnostic Microbiology,** Sixth Edition. Washington Wim,Jr, Stephen Allen, William Janda, Elmer Koneman, GarynProcop, Paul Schreckenberger, Gail Woods.
29. **Huw DW., Volker.B., Jacob. G.B., Ben. R., James. E.A.** Hypertonic saline therapy in cystic fibrosis: do population shifts caused by the osmotic sensitivity of infecting bacteria explain the effectiveness of this treatment. Frontier in Microbiology.2010;1:1-5.
30. Prevalence and risk factors of Metallo-β- lactamase producing Pseudomonas and Acinetobacter species in burns and surgical wards in a tertiary care hospitals . J labs Physicians 2012 Jan;4 (1): 39-42 doi 10.4103/0974-2727.95670.

31. **David Greenwood, Richard Slack, John Peutherer, Mike Barer.** Medical Microbiology. Seventh Edition.
32. **Connie R. Mahon, Donald C.Lehman, George Manuselis, et l.,** Textbook of Diagnostic Microbiology. 3rd Edition.
33. **Delissalde. F., Aibile Cuevas CF**. Comparision of antibiotic susceptibility and plasmid content, between biofilm producing and non-producing clinical i solates of *Pseudomonas aeruginosa*. Antimicob Agents. 2004 Oct;24(4):405-8.
34. **Elkhatib WF, Haynes VL, Noreddin AM**. Unexpected induction of resistance *Pseudomonas aeruginosa* biofilm to fluoroquinolons by diltiazem: a new perspective of microbiological drug-drug interaction.J.Infect. Public health. 2008;1(2):105-12.
35. **David M. Livermore**. Acquired carbapenemases. Journal of Antimicrobial Chemotherapy.1997;39: 673-676.
36. **Bush, K.** New Beta-lactamases in Gram-negative bacteria: diversity and impact on the selection of antimicrobial therapy. Clin. Infect. Dis.2001;32 :1085-1089.
37. **Poole, K.2001.** Multidrug efflux pumps and antimicrobial resistance in *Pseudomonas aeruginosa* and related organisms. J.Mol. Microbiol. Biotechnol.3:255-264.
38. **Keith Poole.** *Pseudomonas aeruginosa*: resistance to the max. Frontiers in Microbiology.Cellular and infection Microbiology.April 2011; 2(65):1-7.
39. **Rasmussen, B.A., Bush,K.** Carbapenem-hydrolysing beta-lactamases. Antimicrobial Agents and Chemotherapy.1997; 41: 223-32.
40. **Rasumussen, B.A., Bush, Tally, F.P.** Antimicrobial resistance in Bacteroids. Clinical Infectious Diseases .1993;16, Suppl. 4: S390-S400.
41. **Timothy Palzkill.** Metallo β Lactamase structure &function.*Annals of the NewYork Academy of Science.* 1277(2013)91-104.
42. **Yong D., Tolemann MA, Giske CG, Cho HS, Sundeman K, Lee K etal.** Characterization of New Delhi Metallo beta lactamase genes, Bla(NDM-1), and a nobel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. *Antimicrobe agents chemother* 2009;53:5046-54

43. Detection of *enterobacteriacae* isolates carrying Metallo beta lactamase-United States, 2010. *MMWR Morb Mortal Wkly Rep* 2010; 59:750

44. **kumarsammy KK, Tolemann MA, Walsh TR, Bagaria J, Butt F, Balkrishnan R,** *etal*. Emergence of new antiobitic resistance mechanisms in India, Pakistan and The U.K.: A molecular, biological, and epidemiological study. *Lancet Infect Dis* 2010;10:597-602.

45. **kush JB, Tandros M, Simor A, Low DE, McGeer AJ, Willey BM,** *etal*. New Delhi Metallo beta lactamase- 1: Local acquisition in Ontario, Canada, and challenge in detection. *CMAJ* 2011;183:1257-61.

46. **Jovcic B, Lepsanovic Z, Suljagic V, Rackov G, Begovic G, Topisirovic L,** *etal.* Emergence of NDM-1 Metallo beta lactamase in pseudomonas *aeruginosa* clinical isolates from Serbia. *Antimicrobe agents chemother* 2011; 55:3929-31.

47. **kusradze I, Diene SM, Goderdzishvili M, Rolain JM.** Molecular detection of Oxa carbepenemases gene in multidrug resistant acinetobacter *baumanii* isolates from Iraq and Georgia. *Int J Antimicrobe agents* 2011;38:164-8.

48. **D Andrea MM, Venturelli C, Giani T, Arena F, Conte V, Bresciani P, *etal.*** Persistant carriage and infection by multiresistant *Escherichia coli* ST405 producing NDM-1 carbepenemase: A report on the first Italian case. *J clin microbial* 2011;49:2755-8.

49. **Zavascki AP, Barth AL, Moro AL, Fernandes JF, Martins AF, Ramos F, Goldani LZ.** The influence of metalo-beta-lactamase production on mortality in nosocomial *Pseudomonas aeruginosa* infections. J Antimicrob Chemother.2006 Aug;58(2):387-92.

50. **Arakawa, Y., M. Murakami, K. Suzuki, H. Ito, R.** Wacharotayankun, S. Ohsuka, N.Kato, and M. Ohta. A novel integron-like element carrying the metallo-β-lactamase gene blaIMP.Antimicrob. Agents Chemother. 1995;39: 1612-1615.

51. **Poirel. L, Lambert.T, Turkoglu. S, Ronco.E, Gaillard.J, Nordman.P.** Characterization of class I integrons from P.aeruginosa that contain the blaVIM2 carbapenem-hydrolyzing betalactamase gene and of two novel aminoglycoside resiistance gene cassettes. *Antimicrob. Agents Chemother*.2001;45:546-552.
52. **Navaneeth BV, Sridaran D, Sahav D, Belwadi MR.A** preliminary study on MBL producing *Pseudomonas aeruginosa* in hospitalized patient. Indian journal of Medical Research.2002; 116:264-7.
53. **David Landman, Simona Brau, Sandeep Kochar, Monica Panwar, Manoj Trehan, Mehmet Doymaz, et al.,** Evolution of antimicrobial resistance among *Pseudomonas aeruginosa ,Acinetobacter baumannii* and *Klebsiella pneumonia* in Brooklyn, NY. Journal of Antimicrobial Chemotherapy .2007; 60, 78-82.
54. **Shanthi M, Sekar U.** Multi-drug resistant *Pseudomonas aeruginosa* and *Acinetobacter baumannii* infections among hospitalized patients: risk factors and outcomes. J Assoc physicians India. 2009 sep; 57:636-645.
55. **Wang, J., Zhou, J.Y., Qu, T.T., Shen, P., Wei, Z.Q.,Yu, Y.S., and Li,L.J.** Molecular epidemiology and mechanisms of carbapenem resistance in *Pseudomonas aeruginosa* isolates from Chinese hospitals. Int.J.Antimicrob. Agents.2010;35:486-491.
56. **Dong F, Xu Xw, Song WQ, Yang YH, Shen XZ.** Analysis of resistant genes of beta-lactam antibiotics form *Pseudomonas aeruginosa* in pediatric patients. Zhonghua Yi Xue Za Zhi. 2008 Nov 18;88(42):3012-5.
57. **Dhara M, Kouda S, Onodera M, et al.,** Molecular characterization of Imipenem resistant *Pseudomonas aeruginosa* in Hiroshima, Japan. Microbiol Immunol. 2007;51(3):271-7.
58. **Quinones-Falconi F, Galicia – Velasco M, Marchiaro P, et al.** Emergence of *Pseudomonas aeruginosa* strains produning metallo-beta-lactamases of the IMP-15 and VIM-2 types in Mexico.Clinical Microbiology and infection.2009may;16:1-4.
59. **Masaru Ohara, Shuntaro Kouda, Makoto Onodera,Yoshihiro Fujiue, Megumi Sasaki, Tadahiro Kohara et al.** Molecular Characterization of

Imipenem-Resistant *Pseudomonas aeruginosa* in Hiroshima, Japan. Microbiology immunology. 2007;51(3):271-277.

60. **CLSI**. *Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fourth Informational Supplement.* CLSI document M100-S24. Wayne, PA: Clinical and Laboratory Standards Institute; 2014.
61. **Collee JG, Diguid JP, Fraser AG,** Mackie and McCartney practical Medical Microbiology. 14 th ed.(Churchill livingstone, Edinburgh) 1996.
62. **Vandepitte J, Vehaegan J, Engbaek K, Rohner P, Piot P, and HeuckC**. C. Bacteriological investigations. In: World Health Organization (2nd), Basic Laboratory Procedures in Clinical Bacteriology, WHO, Geneva, 2003: pp. 20-74.
63. **Amjad A, Mirja IA, Abbasi SA, Farwa U, Malik N, Zia F.** Modified Hodge Test (2011): A simple and effective test for detection of carbepenemase production. Iran. J. Microbiol. 3(4): 189-193.
64. **Yong D, Lee K, Yum JH, Shin HB, Rossolini GM, Chong Y.** Imipenem-EDTA disk method for differentiation of metallo-β-Lactamases producing clinical isolates of *Pseudomonas* spp. And *Acinetobacter* spp. J Clin Microbiol 2002;40:3798-801.
65. **Walsh T, Bolmström A, Quarnström A *et al.*** Evaluation of a new Etest for detecting metallo-β-lactamases in routine clinical testing. *J Clin Microbiol* 2002; **40**:2755-
66. **Livermore DM.** (1995).β-Lactamases in laboratory and clinical resistance. *Clin Microbiol Rev* **8**(4), 557-584.
67. **Samuelsen Q., Toleman MA, Sundsfjord A., Rydberg J., Leegaard TM, *et al*.** (2010). Molecular Epidemiology of Metallo-B-Lactamase-Producing *Pseudomonas aeruginosa* Isolates from Norway and Sweden Shows Import of International Clones and Local Clonal Expansion. *Antimicrob Agents Chemother* **54**(1), 346-352.
68. **Miriagou, V., Tzelepi, E., Gianneli, D., Tzouvelekis, L.S.,** 2003. Escherichia coli with a selftransferable, multiresistant plasmid coding for metallo-β-lactamase VIM-1. Antimicrob. Agents Chemother. 47, 395–397.

69. **Senda, K., Arakawa, Y., Ichiyama, S., Nakashima, K., Ito, H., Ohsuka, S., Shimokata, K.,Kato, N., Ohta, M.,** 1996. PCR detection of metallo-β-lactamase gene (blaIMP) ingram-negative rods resistant to broad-spectrum beta-lactams. J. Clin. Microbiol. 34,2909–2913.
70. **Cornaglia G, Giamarellou H, Rossolini GM.** Metallo-β-lactamase: a last frontier for β-lactams? Lancet Inect Dis 2011;11:381-393.
71. **Arakawa Y., Stibata N., Shabayama K., Kurikawa H., Yagi T., Sujiwara K.** Convient test for screening metallo β-lacatmase producing Gram- negative bacteria by using thiol compound. Journal of Clinical Microbiology; 2000, 38(1): 40-43.
72. **Pfeifer Y., Willharm G, Zander E, Wichelhaus TA, Gottig S, Hunferld KP et al.** Molecular charecterization of Bla NDM 1 in Acinetobacter Baumannii strain isolates in Germany in 2007. J Antimicrob. Chemother. 2011:,66:1998-2001.